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Abstract: Four federally funded randomized placebo-controlled treatment trials of post-treatment Lyme syndrome in the 
United States have been conducted. Most international treatment guidelines summarize these trials as having shown no 
acute or sustained benefit to repeated antibiotic therapy. The goal of this paper is to determine whether this summary con-
clusion is supported by the evidence.  
Methods: The methods and results of the 4 U.S. treatment trials are described and their critiques evaluated.  
Results: 2 of the 4 U.S. treatment trials demonstrated efficacy of IV ceftriaxone on primary and/or secondary outcome 
measures. 
Conclusions: Future treatment guidelines should clarify that efficacy of IV ceftriaxone for post-treatment Lyme fatigue 
was demonstrated in one RCT and supported by a second RCT, but that its use was not recommended primarily due to 
adverse events stemming from the IV route of treatment. While repeated IV antibiotic therapy can be effective, safer 
modes of delivery are needed.  
Keywords: Lyme disease, Chronic Lyme disease, Lyme Encephalopathy, Post-treatment Lyme Disease Syndrome, Clinical 
Trials, Treatment Guidelines. 
 In 2006, the Infectious Diseases Society in the United 
States updated its treatment guidelines for Lyme and other 
tick-borne diseases [1]. Since then other national and interna-
tional organizations have published similar treatment guide-
lines, including the American Academy of Neurology [2], 
the British Infection Association [3], and the European Fed-
eration of Neurological Societies [4]. Based on the results 
from the U.S. clinical trials on post-treatment Lyme disease, 
these guidelines provide parameters for the treatment of pa-
tients with chronic persistent symptoms. These published 
guidelines state “antibiotic therapy has not proven to be use-
ful” [1], “American trials have demonstrated that additional 
prolonged antimicrobial treatment is ineffective in Post 
Lyme Disease Syndrome” [4], and “studies of prolonged 
antimicrobial treatments of patients with Post Lyme Syn-
drome have not shown sustained benefit” [3].  
 It is the contention of the authors of this paper that these 
national and international treatment guidelines, while accu-
rate and informative in most areas, overlook or inappropri-
ately dismiss some of the key lessons learned from the NIH-
funded U.S. Treatment trials on chronic post-treatment Lyme  
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syndrome. Expert committees have carefully reviewed and 
critiqued these studies, highlighting both their limitations 
and the adverse events associated with retreatment [1,5,6]. 
We will address these critiques in detail, focusing in particu-
lar on the study of post-treatment Lyme syndrome which 
enrolled patients based on fatigue [7] as it was this study that 
had the clearest positive findings. We conclude this paper by 
recommending issues to consider in the design of future clin-
ical trials based on the lessons learned from these Lyme dis-
ease treatment studies.  
 Terms. Post-treatment Lyme disease syndrome (a.k.a. 
post-Lyme disease syndrome, post-treatment chronic Lyme 
disease) is a term used to describe the clinical experience of 
patients who have symptoms that persist for months or years 
despite having received recommended courses of antibiotic 
therapy for well-documented Lyme disease [8,9]. Typically 
these patients report problems with fatigue, musculoskeletal 
pain, and cognition [9]. The word “syndrome” reflects an 
acknowledgment that the cause of the persistent symptoms is 
unclear. The term “chronic Lyme disease” is less widely 
favored based on the argument that acute Lyme disease is 
caused by a known infection whereas the chronic post-
treatment symptoms are of uncertain etiology [5]. For the 
purposes of this paper, the term post-treatment Lyme disease 
syndrome (PTLDS) will be used. Exact criteria for PTLDS 
vary. The most inclusive approach encompasses all patients 
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with persistent significantly distressing or impairing symp-
toms that emerge within a defined period after having ac-
quired and been treated for well-documented Lyme disease. 
Operationalized criteria for PTLDS have been proposed that 
are more restrictive, excluding the diagnosis of PTLDS if 
objective signs of disease are present [1]. These operational 
criteria do not clarify how extensive an evaluation is needed 
to conclude that an ‘objective’ deficit is not present. For ex-
ample, for an individual with subjective cognitive com-
plaints, does one require neurocognitive testing and, if so, 
what level of deficit is required to qualify for objective im-
pairment? Or, if a patient complains of subjective 
paresthesias, does one then need to conduct skin biopsies on 
all patients to determine if a small fiber neuropathy is pre-
sent? These questions remain unresolved. The U.S. clinical 
trials on chronic symptoms therefore vary in the criteria for 
enrollment of patients with chronic persistent symptoms. 
While some trials included all patients with symptoms of 
certain severity after well-documented Lyme disease regard-
less of whether objective signs of disease were present [7], 
other studies required objective operationalized criteria [10] 
while others excluded those with objective evidence of dis-
ease on physical examination (e.g., synovitis) [11].  
US CLINICAL TRIALS 1 & 2 (KLEMPNER et al., 
NEW ENGLAND JOURNAL OF MEDICINE 2001)  
 These two placebo-controlled randomized trials [11] used 
the same study design and outcome measures with the dis-
tinguishing feature that one trial enrolled seropositive pa-
tients while the other trial enrolled seronegative patients. The 
total sample size was 129 patients. The treatment period was 
90 days: 30 days of IV ceftriaxone (2 gms/day) followed by 
60 days of oral doxycycline (100 bid) or 30 days of IV pla-
cebo followed by 60 days of oral placebo. After treatment, 
the patients were followed for 90 days. The primary outcome 
measures at 6 months were categorical variables based on 
change from baseline on the physical and mental health-
related quality of life composite indices of the Short form 
general health survey (SF-36)(trichotomized to “worsening”, 
“no change” or “improvement”) [12]. Secondary outcome 
measures assessed change in neurocognition and in psychiat-
ric symptoms. For the seropositive patients entrance criteria 
did not require documentation of classic symptoms of Lyme 
disease, but did require documentation of having received 
recommended treatment for Lyme disease. For the 
seronegative patients, entrance criteria required documenta-
tion of an erythema migrans rash. Additionally, patients had 
to report functional impairment related to musculoskeletal or 
cognitive symptoms that had begun within 6 months of the 
infection and that had been present for at least 6 months (but 
less than 12 years). Patients were excluded if they had re-
ceived more than 60 days of prior IV antibiotics, had known 
hypersensitivity to study medications, had active synovitis or 
positive PCR for Bb in the CSF or blood.  
 At six months, no placebo-drug differences were noted 
for change on the primary outcome measure of the SF-36 
using a preset cutoff for improvement; this was true for the 
seropositive patients, the seronegative patients, and both 
groups combined. In addition, no placebo-drug differences 
were noted for change on the secondary outcome measures 
of cognition and depression. In these studies, the treatment 
was reported as ineffective and it was not clinically recom-
mended.  
 Limitations of this study include: a) not requiring docu-
mentation of objective manifestations of Lyme disease for 
enrollment of all study patients; b) not requiring that patients 
meet a specific severity level for impairment on the primary 
measure of interest at the start of the study; c) inadequately 
sensitive data analytic methodology: (i) not including in the 
analytic method an adjustment for baseline levels of impair-
ment (even though in the seronegative sample there was a 
significant baseline difference on the SF-36), (ii) no assess-
ment for the potential moderating effect of baseline level of 
impairment on treatment outcome, and (iii) using a statisti-
cally inefficient test for comparison between the groups (e.g., 
categorizing a variable that is measured continuously); and 
d) a low dose of oral doxycycline that would not be adequate 
for CNS penetration. By not requiring documentation of the 
signs of Lyme disease, it cannot be certain that all patients in 
the study had had objective manifestations of Lyme disease 
previously. The exclusion of patients with post-treatment 
active synovitis would be consistent with the IDSA’s defini-
tion of PTLDS [1] as this would be an objective finding on 
clinical exam, however patients with other objective findings 
(e.g., cognitive impairment on testing or elevated protein in 
the CSF) weren’t excluded. Although patients who enrolled 
in this study were required to report that their symptoms led 
to functional impairment and the patients as a group did re-
port substantial physical impairment, this study differed from 
the subsequent studies by not requiring a predetermined se-
verity level for enrollment on the primary outcome measure 
of interest. While the mean impairment on the physical com-
posite measures of the SF-36 was moderately severe for the 
group as a whole, the distribution may have included some 
patients who had such low levels of impairment that a treat-
ment effect would have been hard to demonstrate even with 
a potent treatment. The sample of patients in this study, un-
like the two subsequent studies [7,10], was therefore a heter-
ogeneous collection of patients with respect to severity and 
baseline level of impairment. Not adjusting for baseline lev-
els in the main analyses may have decreased the power of the 
test, since baseline levels of impairment typically are related 
to post treatment scores and change scores. Power was fur-
ther decreased by categorizing the change scores and prema-
ture study discontinuation which lowered the final sample 
size. Because the analytic method did not include an assess-
ment of the potential interaction effect of baseline severity 
and treatment group on outcome, true treatment effects dis-
tinguishing the drug and placebo groups (e.g., larger drug 
effects among more impaired subjects) may have been 
missed. Two patients given active treatment had a serious 
adverse event – pulmonary embolus in one and fever, ane-
mia, and GI bleeding in the other. Particular strengths of 
these two studies were the relatively large sample size and 
the requirement that the seronegative patients have a history 
of physician documented erythema migrans.  
U.S. CLINICAL TRIAL 3 – “STOP-LD” STUDY. 
(KRUPP et al., NEUROLOGY, 2003) 
 This randomized double-masked placebo-controlled trial 
of post-Lyme syndrome [7] enrolled 55 patients with persis-
tent severe fatigue at least 6 or more months after antibiotic 
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therapy. Patients had to provide physician documentation of 
previously having met objective criteria for Lyme disease 
(EM or CDC-defined late manifestation of Lyme disease 
confirmed by ELISA and Western blot serology) and of hav-
ing been previously treated with at least 3 weeks of antibiot-
ics six months or more before study entry. Patients were ex-
cluded who had concurrent disorders not related to Lyme 
disease that could cause fatigue. For study entry, patients had 
to have at least moderate fatigue as assessed by the score on 
the Fatigue Severity Scale-11 (FSS-11) that occurred in con-
junction with onset of Lyme disease. Patients were not ex-
cluded if they had observable neurologic findings or other 
objective deficits on routine general or neurologic examina-
tion. Patients received 28 days of IV ceftriaxone or placebo 
following by 5 months of no treatment. The primary out-
come time point was 6 months. Although there were two 
primary clinical measures (fatigue and cognitive response 
time) and one biological measure (an experimental measure 
of CSF infection - Osp A), at the time of enrollment impair-
ment was required only on the fatigue measure. Meaningful 
improvement on the FSS-11 was assessed categorically with 
responder status determined by a decrease of 0.7 points or 
more. Meaningful improvement on the response time meas-
ure required a change of 25% or more. The results demon-
strated that significantly more patients assigned to ceftriax-
one showed improvement in disabling fatigue compared to 
the placebo group (RR 3.5, p<0.001). No drug-placebo dif-
ference was noted in cognitive response time or in Osp A. 
Four patients (3 on placebo) had adverse events that required 
hospitalization. The authors, while concluding that ceftriax-
one did result in improvement in severe fatigue, concluded 
that the risks associated with treatment and the lack of bene-
fit in other outcome measures mitigated against recommend-
ing repeated antibiotic therapy.  
 Among the 4 post-treatment Lyme syndrome studies, the 
STOP-LD study is the one that most clearly demonstrated 
efficacy for drug over placebo on a primary outcome meas-
ure. Perhaps because of this, the study results have been 
carefully scrutinized and critiqued [1,5]. In the comments 
below, we review each of these critiques to evaluate their 
merit in either supporting or dismissing the favorable effica-
cy result of the study.  
Critique #1 :“Only 1 of 3 Primary Outcome Measures 
Showed a Treatment Effect”  
  The 3 outcome measures were: a) Fatigue Severity 
Scale; b) a cognitive test of mental processing speed; and c) 
clearance of Borrelial Osp A antigen.  
 a. Fatigue. Improvement was noted on the only primary 
outcome measure on which patients were enrolled. The Fa-
tigue Severity Scale (FSS-11) was employed as the primary 
enrollment measure and as the primary outcome measure for 
fatigue, as this is a measure that had been psychometrically 
validated by the authors. On this fatigue measure, the per-
centage of responders to drug was high (64%) compared to 
placebo (18.5%) (p<0.001). In other words, based on this 
measure, the drug treatment was effective. To appropriately 
assess efficacy of a treatment, patients in a controlled trial 
must have meaningful impairment on the measure of interest 
at the start of the study. Given that all patients were required 
to have prominent fatigue at the start of the STOP-LD study, 
it is reasonable for fatigue to have been a primary outcome 
measure to assess efficacy. On the other outcome measures 
however (cognitive processing speed or Osp A antigen), pa-
tients were not enrolled based on presence of impairment or 
abnormality; (e.g., only 9 of the 55 patients were positive for 
Osp A antigen at baseline). This study therefore was not able 
to adequately test efficacy on these latter measures.  
 The therapeutic effect of additional IV ceftriaxone thera-
py on the fatigue measure was demonstrated even more ro-
bustly within the subgroup of study participants who at the 
time of enrollment were serologically IgG Western blot posi-
tive. In this more homogenous subgroup, the responder rate 
for the drug treated group was 6 times higher than in the pla-
cebo treated group (80% vs 13%, p<0.01). See Fig. (1). 
 A critique of the fatigue study result has been that while 
there was a responder rate difference on the primary fatigue 
severity scale measure, there was no significant improve-
ment in fatigue as assessed by a secondary visual analog 
 
Fig. (1). Percentage of Responders on Fatigue Severity Scale in 2 placebo controlled trials of post-treatment Lyme disease. 
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scale (VAS) of fatigue intensity. The VAS, however, was a 
secondary measure whose validity was not clearly estab-
lished, and may have simply been a less sensitive scale. 
Never the less, the authors of this study themselves note that 
the VAS results were consistent with the FSS-11 results: 
“The change in the fatigue VAS showed a similar pattern to 
the FSS-11, with a trend toward more improvement in the 
ceftriaxone vs the placebo group at 6 months (p=0.08). In 
addition, at 6 months, the mean (SD) VAS scores were lower 
in the ceftriaxone than in the placebo group (4.8 (2.5) vs 6.5 
(2.1); p=0.01)”.  
 b. Cognitive slowing. The authors of this study defined a 
25% improvement in cognitive response time as a clinically 
meaningful response. Although the authors note that the en-
rolled Lyme patients had worse response time scores than 
historical normative controls, they do not clarify how many 
patients in this study actually were impaired on this measure. 
In the discussion, they emphasize that the observed cognitive 
deficits were “relatively mild, which may have contributed to 
the lack of a treatment effect on cognition”. This important 
point highlights a key issue: if patients aren’t sufficiently 
impaired, a treatment effect is unlikely to be seen even with 
a very potent treatment. Given the small sample size of this 
study and the lack of major impairment on this outcome 
measure at the time of enrollment, statistical power is limited 
to demonstrate a treatment effect on this measure. This study 
most likely was not adequately powered to assess the effica-
cy of drug vs. placebo on cognitive slowing.  
 c. Clearance of Osp A antigen. There are problems with 
this as an outcome measure. First, this is an experimental test 
of uncertain sensitivity and specificity. Second, presence of 
the Osp A antigen was detected in only 9 of 55 patients; a 
primary efficacy assessment of change in response to treat-
ment cannot be based on a sample size of 9. The study was 
under-powered to detect any realistic change in clearance of 
OspA antigen. As noted by the authors, “The primary bio-
logic outcome measure, CSF OspA antigen, was present in 
only 16% of patients at baseline and was not a useful marker 
of outcome”. The study results therefore using this primary 
outcome measure should not be included in the final deter-
mination of whether IV ceftriaxone is effective as a treat-
ment for PTLDS.  
 Summary. This study was adequately powered to test 
only one of the 3 primary outcome measures: the only clini-
cal measure on which patients were enrolled (ie, fatigue) and 
on which they were definitively impaired. For the disabling 
fatigue commonly seen among patients with PTLDS, sus-
tained efficacy using IV ceftriaxone was demonstrated.  
Critique #2: “The Favorable Results on Fatigue may 
have Occurred due to Inadvertent Unmasking of the 
Treatment” 
 In this study, when patients were asked at the 6 month 
time points to guess the treatment to which they had been 
randomized, significantly more patients in the ceftriaxone 
group correctly guessed their treatment assignment com-
pared to the placebo group. While this result certainly raises 
the possibility that masking was compromised, the following 
points are worth noting. 
 a. “Unmasking” effects are inherently ambiguous. This 
same result could lead to the possible explanation that people 
guessed correctly because the drug had a positive effect on 
their symptoms. If patients experience meaningful improve-
ment, they will more likely guess that they are on active 
treatment. In other words, if an active treatment works, the 
patients on that treatment should guess their treatment as-
signment correctly more often than patients given a treat-
ment that doesn’t work. Since there was no significant dif-
ference between the two treatments with respect to adverse 
effects (another possible source of unblinding), this may lead 
one to hypothesize that the higher correct guess rate in the 
ceftriaxone group was due to the beneficial impact of the 
drug rather than unmasking.  
 b. The authors in the results note that: “at 6 months, 
among patients in both groups who believed they were on 
active therapy, those in the ceftriaxone group still showed a 
higher frequency of improvement in fatigue scores compared 
to those in the placebo group (83% vs 44%).” In other 
words, even among those who believed that they had been 
given active drug, the higher responder rate still persisted 
among those who had in fact received active drug rather than 
placebo.  
 c. Comparable results were obtained in a second study -
the Lyme encephalopathy trial [10] (see Fig. 1). When the 
Lyme encephalopathy results were reanalyzed using compa-
rable methods as in the STOP-LD study, the responder rate 
on the fatigue measure was 66.7% for the ceftriaxone treated 
group vs 25% for the placebo-treated group (p=0.05) at week 
24. This is nearly identical to the 64% vs 19% results for 
drug vs placebo comparison at week 24 (6 months) noted in 
the STOP-LD study. The Lyme encephalopathy study results 
are therefore consistent with the STOP-LD findings, suggest-
ing that the STOP-LD results are valid and not due to inad-
vertent unmasking. 
 d. As previously noted, patients who were IgG Western 
blot positive in this study were 6 times more likely to show 
improvement in fatigue if given ceftriaxone than if they were 
given placebo (80% vs 13%, p<0.01) (Fig. 1). This sub-
grouping, based on a biological marker, enhanced the re-
sponder rate for drug and diminished the responder rate for 
placebo. If the higher responder rate in response to ceftriax-
one were primarily due to “correct guessing”, then there 
shouldn’t be a biologically homogenous subgroup that re-
sponded even better to the active treatment than to placebo. 
This biologically based result speaks to the greater likelihood 
that a true treatment effect was occurring rather than un-
masking.  
STOP-LD Critique #3. “The Magnitude of the Effect on 
Improvement in Fatigue was Small” 
The responder status in this study for the fatigue scale was 
determined based on a change score on the FSS of 0.7 units. 
Based on prior work, the authors determined that a 0.7 unit 
change was “clinically meaningful”, representing “an im-
provement approximately three times as large as that ob-
served in a prior placebo-treated group”. Therefore, based on 
the study design which specified in advance the criteria for a 
clinically meaningful improvement, it is reasonable to con-
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clude that the responders in this study did in fact experience 
clinically meaningful change.  
 In Table 2 of the STOP-LD paper, the mean percentage 
change from baseline was 22.1% for the ceftriaxone group 
and 9.1% for the placebo group. Prior critiques [5] have not-
ed that the difference between active drug and placebo was 
only 13% and then question whether a difference of only 
13% is clinically meaningful. This issue can be further ex-
amined in two ways: 
 a. What was the effect size for the difference in im-
provement between drug and placebo at 6 months? In infer-
ential statistics, an effect size helps to determine whether a 
statistically significant difference is a difference with clinical 
importance. Based on Cohen [13], an effect size of 0.20 is 
considered mild, 0.50 is medium and anything greater than 
0.80 is large. The effect size on the Fatigue Severity Scale in 
the STOP-LD study was 1.0 using their baseline SD values 
for the FSS. (A meaningful analogy from the cognitive realm 
is that an effect size of 1 would represent a 15 point im-
provement in IQ.) A more conservative approach toward 
evaluating effect size would use the baseline SD values for a 
post-Lyme sample that had not been recruited specifically 
for fatigue. The Lyme encephalopathy sample [10] would 
meet this requirement. Using the baseline FSS SD values 
therefore from the encephalopathy sample, the effect size on 
the FSS in the STOP-LD study was 0.63. In other words, a 
more conservative estimate of effect size never the less 
demonstrates that the beneficial impact of ceftriaxone ranged 
from moderate to large. In comparison to drug trials for FDA 
approved anti-depressants in which effect sizes are often 
only mild to moderate [14], this would be considered a ro-
bust behavioral improvement and a valuable treatment.  
 b. Another way to examine this issue is to assess the 
magnitude of improvement in those patients who were re-
sponders vs. those patients who were non-responders. That 
data is not presented in the STOP-LD paper. However, to try 
to shed light on this question, we reexamined the Lyme en-
cephalopathy Fatigue Severity Scale data to determine the 
magnitude of improvement at six months among responders 
if the enrollment were restricted to those who had FSS at the 
start of the study of 4 or higher, as had been done in the 
STOP-LD study. Using the same criteria for responders as 
had been used in the STOP-LD study, our data analysis re-
vealed the following for the percentage improvement at 
week 24 compared to baseline on the fatigue severity scale: 
0.34 (+/-0.20) improvement in fatigue for the responders vs -
0.02 (+/-0.12) change (worsening) in fatigue for the non-
responders. An improvement in fatigue of 34% is likely to be 
clinically meaningful for the two-thirds of the sample who 
experienced this improvement, although it is certainly not 
curative. It is also likely that the magnitude of improvement 
for responders in the STOP-LD study would be even greater 
than in our Lyme encephalopathy study given that patients in 
their sample had received less antibiotic therapy prior to en-
tering the trial.  
 Based on the comments above, therefore, it is unreasona-
ble to discount the improvement in fatigue in the STOP-LD 
study as having been “too small” in magnitude to be of clini-
cal significance. Based on currently accepted methods for the 
analysis of clinical trial data, the effect size for improvement 
in fatigue in the STOP-LD study was moderate to large, and 
would be considered clinically meaningful.  
STOP-LD Critique #4. “The High Drop-out Rate in the 
Placebo Group May have Led to Misleading Results.” 
 According to the published paper, there were 5 drop-outs 
in the placebo-treated group who were not assessed at 6 
months and 2 drop-outs in the drug-treated group who were 
not assessed at 6 months. This is a modest drop-out rate. If 
one conducts a “worst case scenario analysis” which would 
assume that the 5 drop-outs in the placebo-treated group 
would have been responders and the 2 drop-outs in the 
ceftriaxone-group would have been non-responders, then the 
X2 analysis continues to demonstrate significantly more re-
sponders in the drug-treated compared to the placebo-treated 
group (18/28 vs 10/27, X2=4.1, p= 0.04) Based on this analy-
sis, it does not appear that the drop-outs led to misleading 
results.  
U.S. CLINICAL TRIAL 4 – POST TREATMENT 
LYME ENCEPHALOPATHY. (FALLON et al., NEU-
ROLOGY, 2008)  
 This placebo-controlled randomized trial enrolled 37 
patients with post-treatment Lyme encephalopathy. Patients 
were assigned to treatment with 10 weeks of IV ceftriaxone 
or placebo in a 2:1 randomization followed by no treatment 
for 14 weeks. The primary end-points were week 12 for effi-
cacy and week 24 for longer-term durability. As this was a 
study of Lyme encephalopathy, the primary measure of in-
terest assessed cognition, with a specific focus on memory. 
Patients had to have both subjective cognitive complaint and 
objectively confirmed deficits in memory; patients with oth-
er known causes of cognitive impairment were excluded. 
The criteria for the diagnosis of Lyme disease required: a) 
documentation of physician-diagnosed erythema migrans or 
a later manifestation of Lyme disease meeting CDC surveil-
lance criteria with a positive or equivocal ELISA confirmed 
by positive Western blot serology; and b) a positive IgG 
Western blot at the time of study entry. All patients also had 
to have had at least 3 weeks of prior IV ceftriaxone or IV 
cefotaxime treatment for Lyme disease. Because repeated 
neurocognitive testing can result in improvement merely 
because of the practice effect, healthy controls were included 
to control for this effect. There were therefore 3 groups (pa-
tients on drug, patients on placebo, and healthy controls). 
Over the course of the 24 weeks of this study, there was a 
significant group difference (p= 0.04) in cognitive change 
across time among the 3 groups; this difference was attribut-
ed to the initial improvement in overall cognition at week 12 
in the drug group followed by the loss of that improvement 
by week 24. On the drug vs healthy control comparison at 
week 12, the improvement in cognition for the drug-treated 
group was greater than the improvement (presumably from 
the practice effect) noted in the healthy control group (p< 
0.01). On the specific drug vs placebo comparison at week 
12, the preferential improvement for drug in overall cogni-
tion fell at the margin of significance (p= 0.053); because 
this fell at the margin of significance and because the sample 
size was small, this result must be viewed with caution, and 
requires replication for confirmation of a treatment effect, as 
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there is a slightly increased risk that this result occurred by 
chance. In this study, a statistically significant domain by 
treatment interaction effect was not seen; this indicates that 
the improvement in cognition was broadly distributed across 
the six cognitive domains and not specific to the primary 
domain of memory on which the study was powered. On the 
planned analysis of the secondary measures of pain, fatigue, 
and physical functioning, an interaction effect was noted 
with baseline severity such that the benefit of drug over pla-
cebo increased as baseline severity increased; the improve-
ment observed at week 12 was sustained to week 24 for pain 
and physical functioning. Several patients had potentially 
serious side effects (e.g., 2 had thrombus formation at the 
PICC line, 1 had a staphylococcal infection, and 1 had bili-
ary pain and stones that required cholecystectomy). On bal-
ance, given the marginal cognitive benefit at week 12, the 
lack of sustained cognitive benefit to week 24, and the risks, 
the concluding clinical recommendation from this study was 
that repeated IV antibiotic therapy followed by no treatment 
for 14 weeks was not recommended for sustained improve-
ment in cognition.  
 It has been suggested that the initial improvement in cog-
nition during the time of active drug treatment from baseline 
to week 12 may have been a “regression to the mean” effect. 
Fig. (2) demonstrates the change in cognition over time for 
the 3 groups in the Lyme encephalopathy study, indicating a 
comparable slope of improvement in cognitive performance 
over 24 weeks for the placebo and healthy control groups vs. 
a steeper slope of improvement for the drug group from 
baseline to week 12 followed by a decline to week 24. Re-
gression to the mean is unlikely to account for the preferen-
tial improvement in the drug group between baseline and 
week 12 primarily because after drug was discontinued there 
was a regression away from the mean on the cognitive 
scores. While regression toward the mean is a well-
established phenomenon, regression away from the mean is 
not. The improvement during the first 12 weeks (on antibiot-
ics for 10 of these weeks) followed by worsening in the se-
cond 12 weeks (off antibiotics) would be more consistent 
with an active drug treatment effect that was not sustained. 
Also worth noting is that the differences at baseline in the 
drug and placebo groups on cognition were not statistically 
significant. 
 The planned analysis of the secondary outcome measures 
of pain, fatigue, and physical impairment produced interac-
tion effects at week 12 favoring drug over placebo as a func-
tion of baseline severity, with the drug effect increasing with 
higher baseline impairment. As a model-based illustration of 
the study results, Fig. (3) illustrates the improvement in pain, 
fatigue, and physical functioning in the Lyme encephalopa-
thy study as a function of baseline severity. (The middle 
panel (“Pain”) from Fig. (3) is reprinted here with permis-
sion from the journal Neurology [10]). Significant improve-
ment was sustained among these more impaired patients to 
week 24 for the measures of pain and physical functioning. 
These results suggest that for a subgroup of patients with 
more severe impairment in pain or physical functioning, a 
course of repeated IV antibiotic therapy can result in sus-
tained long-term benefit.  
 Limitations of the Lyme encephalopathy study include 
the small sample size which would limit the ability to detect 
less robust treatment effects (n=37 for Lyme patients and 18 
for healthy controls), the relative treatment refractoriness of 
the sample (mean amount of prior therapy: IV 2.3 months, 
oral 7.7 months) which would reduce the likelihood of find-
ing a treatment effect for repeated treatment, and the limited 
generalizability of the study findings given the extremely 
rigorous but narrow criteria used to enter patients.  
 Because this study sample comprised patients with objec-
tively confirmed evidence of cognitive deficits, the distinc-
tion between Lyme encephalopathy and post-treatment Lyme 
disease syndrome was blurred. Although these patients cer-
tainly had the typical post-treatment symptoms of pain, fa-
Fig. (2). Change in Cognition over time for 3 groups in Lyme Encephalopathy Study: patients were given 10 wks of IV ceftriaxone or place-
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tigue, and physical dysfunction, the presence of objective 
impairment in memory raises the question of whether these 
patients would be better defined as having “late Lyme dis-
ease” rather than “post-treatment Lyme disease syndrome”.  
Issues to Consider in Evaluating and Planning Clinical 
Trials 
1. Efficacy vs. Clinically Recommended 
 Each of the U.S. treatment trials on PTLDS have con-
cluded with the recommendation that the course of therapy 
tested in each specific trial was not recommended for ame-
lioration of the symptoms indicated by the primary outcome 
measures. There is a difference however between whether or 
not a treatment is effective and whether or not a treatment is 
recommended. For example, in the STOP-LD trial of post-
treatment Lyme disease, the treatment was shown to be ef-
fective on the primary outcome measure (Fatigue Severity 
scale) on which the patient’s were enrolled; 64% of those 
who received drug were responders compared to 18.5% of 
those who received placebo (p<.001). However, the STOP-
LD article concluded by not recommending repeated antibi-
otic treatment, “particularly in light of the frequency of seri-
ous adverse events”. In other words, the treatment was effec-
tive but it carried risks. Presumably if an alternative antibi-
otic treatment of similar efficacy but improved safety profile 
could be found, then the authors would have concluded that 
repeated antibiotic treatment would be recommended. 
Treatment guidelines that dismiss the research findings as 
showing no efficacy do an injustice to the evidence and are 
not helpful to clinicians and patients. For example, a clini-
cian with a patient suffering from disabling post-Lyme fa-
tigue would want to know that the clinical trials provided 
divergent results to enable a thoughtful discussion of the 
risks and benefits of repeated antibiotic therapy, as a patient 
with severe fatigue may decide that the potential benefit of 
sustained improvement outweighs the risks. Treatment 
guidelines then should make clear the distinction between 
efficacy demonstrated in a placebo controlled trial and clini-
cal recommendation based on a composite consideration 
which includes efficacy and adverse effects. 
2. Treatment Refractoriness of the Sample 
Consideration needs to be given to the amount of prior anti-
biotic therapy received by the recruited sample. For example, 
a study composed of patients who had 4+ months of prior 
antibiotic therapy for Lyme disease may come up with nega-
tive results. However, if that same study had recruited a less 
treatment refractory sample (e.g., composed of patients who 
had received no more than 2 months previously), a treatment 
effect may be detectable.  
3. Sample Size and Power 
 Efficacy studies are powered based on the degree of ex-
pected improvement in the outcome measure of interest. In 
other words, a sufficient sample size is needed to test a hy-
pothesis and the sample size is determined based on the 
magnitude of the expected effect. Clinical trials containing 
only a small sample size would therefore only be able to 
detect drug effects that are large. As the sample size increas-
es, the study then becomes able to differentiate drug vs pla-
cebo differences of lesser magnitude. With this in mind, it is 
worth noting that the sample sizes employed in the chronic 
Lyme disease trials have been relatively small and thus 
would only be able to detect large drug vs placebo differ-
ences: Fallon et al., (37 Lyme patients); Krupp et al., (55 
patients); Klempner et al., (115 patients). That one (STOP-
LD) of these studies had results indicating a significant clini-
cal benefit for repeated antibiotic therapy on a key primary 
outcome measure is remarkable given the small sample size 
and reinforces the conclusion that the treatment was an agent 
of change (rate ratio>3.5).  
4. Study Design and Analytic Method 
 In general, the more homogeneous a sample, the more 
sensitive will be the trial to test a hypothesis regarding 
treatment effects. Sample heterogeneity, on the other hand, 
may result in low signal to noise ratio that makes signal de-
tection more difficult. This issue is of particular concern 
when sample sizes are small. This is a well known design 
issue in research studies. When patients are not recruited 
 
Note: High scores on fatigue and pain and low scores on physical functioning indicate greater severity. 
Fig. (3). Model-based Illustrations from Lyme Encephalopathy Study: change over time as a function of baseline severity on measures of 
Fatigue, Pain, and Physical Functioning. 
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based on a particular severity level for the outcome measure 
of primary interest, it is then possible that the study will in-
correctly show no difference between drug and placebo – a 
Type II error. To address this potential weakness in the study 
design, if an outcome variable does not have a minimum 
severity cutoff for enrollment, data analytic methods should 
assess the moderating effect of baseline severity on outcome. 
This is usually done by examining the potential interaction 
between baseline severity and treatment group with regard to 
outcome. The two studies that demonstrated a treatment ef-
fect [7, 10] did address this study design issue, while the two 
studies that showed no effect [11] did not. 
SUGGESTIONS FOR FUTURE TREATMENT 
GUIDELINES 
 Based on the evidence cited above, one cannot conclude 
that repeated antibiotic therapy is ineffective in improving 
certain symptoms associated with post-treatment Lyme dis-
ease syndrome. Nor can it be concluded that repeated antibi-
otic therapy is robustly effective. One can conclude however 
that approximately 60% of patients with persistent post-
treatment Lyme fatigue may experience meaningful but par-
tial clinical improvement in fatigue with antibiotic retreat-
ment. Guidelines for Lyme disease that address patients with 
chronic symptoms therefore need to clarify that the con-
trolled trials of additional antibiotic therapy for post-
treatment Lyme symptoms have revealed conflicting results, 
with some studies demonstrating efficacy and others not 
showing benefit to repeated treatment.  
 Specifically, the re-analysis of the results of the chronic 
Lyme trials leads to the following recommendation for the 
text of treatment guidelines. “IV ceftriaxone therapy is mod-
erately efficacious for patients with chronic (>6 months) 
subjective fatigue after recommended antibiotic treatment 
regimens, but the risk associated with IV antibiotic therapy 
requires careful discussion with the patient of the cost-
benefit ratio. Sustained improvement from IV ceftriaxone 
therapy for other PTLDS symptoms such as physical dys-
function and pain is uncertain, with positive results suggest-
ed by one study but not by other studies.” 
FINAL COMMENTS 
 The conclusions of this analysis of the chronic Lyme 
trials emphasize the benefits of repeated antibiotic therapy 
for patients with specific chronic symptoms. This is done as 
a counterbalance to the majority of published guidelines 
which overlook and/or dismiss the evidence that demon-
strates that additional antibiotic therapy can lead to sustained 
benefit. We hope that our review will lead to more carefully 
detailed and balanced summaries in future guidelines. How-
ever, we also wish to emphasize that while some patients do 
improve with repeated antibiotic therapy, other patients with 
persistent symptoms do not. Further, as the clinical trials also 
demonstrate, antibiotic therapy particularly when given in-
travenously can put the patient at serious risk.  
 Biomarkers are needed that can help clinicians to dis-
criminate in advance which patients are more likely to bene-
fit from repeated antibiotic therapy vs. those for whom such 
treatment is unlikely to be beneficial. Future studies must 
also begin to address non-antibiotic strategies to help im-
prove persistent symptoms. Recent serologic and CSF stud-
ies of patients with post-treatment Lyme disease syndrome 
suggest that a persistently activated immune response may 
play a role in the pathophysiology of chronic symptoms [15, 
16] . Clarification of whether these findings are of pathogen-
ic relevance and whether this immune activation is due to 
persistent antigenic stimulation (as might occur from persis-
tent Borrelia) or from a post-infectious autoimmune process 
would be quite beneficial to clinicians seeking to identify 
more effective and appropriately targeted treatments for the-
se patients. 
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